...
首页> 外文期刊>Journal of Neuro-Oncology >Loss of Heterozygosity for Loci on Chromosome Arms 1p and 10q in Oligodendroglial Tumors: Relationship to Outcome and Chemosensitivity
【24h】

Loss of Heterozygosity for Loci on Chromosome Arms 1p and 10q in Oligodendroglial Tumors: Relationship to Outcome and Chemosensitivity

机译:少突胶质细胞瘤中染色体臂1p和10q上基因座的杂合性丧失:与结果和化学敏感性的关系

获取原文
获取原文并翻译 | 示例
           

摘要

Oligodendroglial tumors frequently have deletions of chromosomal loci on 1p and 19q. Loss of heterozygosity (LOH) of chromosome 10 may be a negative prognostic factor. We reviewed 23 patients with oligodendroglial tumors, to evaluate the frequency of 1p and 10q LOH and correlate with clinical outcome. Three loci (D1S402, D1S1172, MCT118) on 1p and 2 loci (D10S520 and D10S521) on 10q were analyzed for LOH using PCR techniques. Sixteen oligodendrogliomas (6 low grade and 10 anaplastic) and 7 oligoastrocytomas (1 low grade and 6 anaplastic) were studied. Overall 14/22 (64%) showed 1p LOH and 7/23 (30%) showed 10q LOH. Of 7 patients with some response to chemotherapy, all showed 1p LOH and none had 10q LOH. Of 5 patients with stable or progressive disease, 1 had 1p LOH and 2 showed 10q LOH. The presence of 1p LOH was significantly associated with response to chemotherapy (p = 0.02). Median progression free survival (PFS) was 31 months for 1p intact patients and 118 months for the 1p LOH group (p = 0.014). Median PFS for 10q LOH patients was 31 and 118 months for patients with intact chromosome 10 (p = 0.016). 1p LOH is a predictor of response to chemotherapy and a good prognostic factor. 10q LOH is less common in oligodendroglial tumors but predicts for worse outcome. Molecular genotyping of oligodendroglial tumors is recommended as part of the standard diagnostic workup.
机译:少突胶质细胞瘤通常在1p和19q处具有染色体基因座的缺失。 10号染色体杂合性(LOH)的丧失可能是阴性的预后因素。我们回顾了23例少突胶质细胞瘤患者,以评估1p和10q LOH的频率并与临床结果相关。使用PCR技术分析了1p上的三个基因座(D1S402,D1S1172,MCT118)和10q上的两个基因座(D10S520和D10S521)的LOH。研究了16例少突胶质细胞瘤(6例低级和10变性)和7例少突星形细胞瘤(1例低级和6变性)。总体14/22(64%)显示1p LOH,7/23(30%)显示10q LOH。在对化疗有一定反应的7例患者中,所有人均显示1p LOH,而没有10q LOH。在5例稳定或进行性疾病患者中,有1例LOH,2例显示10q LOH。 1p LOH的存在与化疗反应显着相关(p = 0.02)。 1p完整患者的中位无进展生存期(PFS)为31个月,1p LOH组为118个月(p = 0.014)。完整10号染色体患者的10q LOH患者中位PFS为31和118个月(p = 0.016)。 1p LOH是化学疗法反应的预测指标,也是良好的预后因素。 10q LOH在少突胶质细胞瘤中较不常见,但预测结果会更差。建议将少突胶质细胞瘤的分子基因分型作为标准诊断检查的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号